Original Articles Clinical Investigations
MicroRNA-155 is a predictive marker for survival in patients with clear cell renal cell carcinoma
Article first published online: 10 OCT 2012
© 2012 The Japanese Urological Association
International Journal of Urology
Volume 20, Issue 5, pages 468–477, May 2013
How to Cite
Shinmei, S., Sakamoto, N., Goto, K., Sentani, K., Anami, K., Hayashi, T., Teishima, J., Matsubara, A., Oue, N., Kitadai, Y. and Yasui, W. (2013), MicroRNA-155 is a predictive marker for survival in patients with clear cell renal cell carcinoma. International Journal of Urology, 20: 468–477. doi: 10.1111/j.1442-2042.2012.03182.x
- Issue published online: 5 MAY 2013
- Article first published online: 10 OCT 2012
- Manuscript Accepted: 5 SEP 2012
- Manuscript Received: 9 MAR 2012
- Grants-in-Aid for Cancer Research from the Ministry of Education, Culture, Science, Sports, and Technology of Japan
- hypoxia-inducible factor-1α;
- micro-ribonucleic acid;
- micro-ribonucleic acid-155;
- quantitative reverse transcript polymerase chain reaction;
- renal cell carcinoma
To investigate the clinical significance of micro-ribonucleic acid-155 in clear cell renal cell carcinoma, in particular focusing on the association of expression levels of micro-ribonucleic acid-155 with clinicopathological factors, cancer-specific survival and therapeutic outcomes in clear cell renal cell carcinoma patients.
Quantitative reverse transcription polymerase chain reaction of micro-ribonucleic acid-155 was carried out on 137 clear cell renal cell carcinoma cases, containing 77 matched pairs of clear cell renal cell carcinoma and normal adjacent kidney tissues from the same patients.
Significant overexpression of micro-ribonucleic acid-155 was found in clear cell renal cell carcinoma compared with normal kidney tissue. Expression of micro-ribonucleic acid-155 was not associated with prognosis in all stage groups. However, in 43 patients with stage III and IV clear cell renal cell carcinoma, low expression levels of micro-ribonucleic acid-155 correlated with a poor prognosis. Regarding cancer-free survival of 26 patients with stage III and IV clear cell renal cell carcinoma who received curative resection and cancer-specific survival of 31 patients who received postoperative therapy with interferon-α after radical nephrectomy, low expression levels of micro-ribonucleic acid-155 correlated with poor clinical outcomes in these two groups.
Low expression of micro-ribonucleic acid-155 represents a valuable marker of poor clinical outcomes in patients with stage III and IV clear cell renal cell carcinoma.